Literature DB >> 28945127

Efficacy of the early administration of valacyclovir hydrochloride for the treatment of neuropathogenic equine herpesvirus type-1 infection in horses.

Lara K Maxwell, Bradford G Bentz, Lyndi L Gilliam, Jerry W Ritchey, Nicola Pusterla, R Eberle, Todd C Holbrook, Dianne McFarlane, Grant B Rezabek, James Meinkoth, Chase Whitfield, Carla L Goad, George P Allen.   

Abstract

OBJECTIVE To determine whether prophylactic administration of valacyclovir hydrochloride versus initiation of treatment at the onset of fever would differentially protect horses from viral replication and clinical disease attributable to equine herpesvirus type-1 (EHV-1) infection. ANIMALS 18 aged mares. PROCEDURES Horses were randomly assigned to receive an oral placebo (control), treatment at detection of fever, or prophylactic treatment (initiated 1 day prior to viral challenge) and then inoculated intranasally with a neuropathogenic strain of EHV-1. Placebo or valacyclovir was administered orally for 7 or 14 days after EHV-1 inoculation or detection of fever (3 horses/group). Effects of treatment on viral replication and clinical disease were evaluated. Plasma acyclovir concentrations and viremia were assessed to determine inhibitory concentrations of valacyclovir. RESULTS Valacyclovir administration decreased shedding of virus and viremia, compared with findings for control horses. Rectal temperatures and clinical disease scores in horses that received valacyclovir prophylactically for 2 weeks were lower than those in control horses. The severity of but not the risk for ataxia was decreased by valacyclovir administration. Viremia was decreased when steady-state trough plasma acyclovir concentrations were > 0.8 μg/mL, supporting the time-dependent activity of acyclovir. CONCLUSIONS AND CLINICAL RELEVANCE Valacyclovir treatment significantly decreased viral replication and signs of disease in EHV-1-infected horses; effects were greatest when treatment was initiated before viral inoculation, but treatment was also effective when initiated as late as 2 days after inoculation. During an outbreak of equine herpesvirus myeloencephalopathy, antiviral treatment may be initiated in horses at various stages of infection, including horses that have not yet developed signs of viral disease.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28945127      PMCID: PMC6440545          DOI: 10.2460/ajvr.78.10.1126

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  8 in total

1.  Assessment of listing and categorisation of animal diseases within the framework of the Animal Health Law (Regulation (EU) No 2016/429): infection with Equine Herpesvirus-1.

Authors:  Søren Saxmose Nielsen; Julio Alvarez; Dominique Joseph Bicout; Paolo Calistri; Elisabetta Canali; Julian Ashley Drewe; Bruno Garin-Bastuji; José Luis Gonzales Rojas; Christian Gortázar; Mette Herskin; Virginie Michel; Miguel Ángel Miranda Chueca; Helen Clare Roberts; Barbara Padalino; Paolo Pasquali; Hans Spoolder; Karl Ståhl; Antonio Velarde Calvo; Arvo Viltrop; Christoph Winckler; Andrea Carvelli; Romain Paillot; Alessandro Broglia; Lisa Kohnle; Francesca Baldinelli; Yves Van der Stede
Journal:  EFSA J       Date:  2022-01-12

2.  Oral Administration of Valganciclovir Reduces Clinical Signs, Virus Shedding and Cell-Associated Viremia in Ponies Experimentally Infected with the Equid Herpesvirus-1 C2254 Variant.

Authors:  Côme J Thieulent; Gabrielle Sutton; Marie-Pierre Toquet; Samuel Fremaux; Erika Hue; Christine Fortier; Alexis Pléau; Alain Deslis; Stéphane Abrioux; Edouard Guitton; Stéphane Pronost; Romain Paillot
Journal:  Pathogens       Date:  2022-05-04

Review 3.  EHV-1: A Constant Threat to the Horse Industry.

Authors:  Fatai S Oladunni; David W Horohov; Thomas M Chambers
Journal:  Front Microbiol       Date:  2019-12-03       Impact factor: 5.640

4.  Pharmacokinetics and analytical determination of acyclovir in Asian elephant calves (Elephas maximus).

Authors:  Siripat Khammesri; Chadarat Ampasavate; Darunee Hongwiset; Raktham Mektrirat; Siriluk Sangsrijan; Janine L Brown; Chatchote Thitaram
Journal:  Vet Anim Sci       Date:  2021-12-24

5.  New Insights into the Management of an EHV-1 (Equine Hospital) Outbreak.

Authors:  Eveline Vandenberghe; Berit Boshuizen; Catherine J G Delesalle; Lutz S Goehring; Katy A Groome; Kees van Maanen; Cornelis M de Bruijn
Journal:  Viruses       Date:  2021-07-22       Impact factor: 5.048

6.  Subcutaneous Administration of Low-Molecular-Weight Heparin to Horses Inhibits Ex Vivo Equine Herpesvirus Type 1-Induced Platelet Activation.

Authors:  Tracy Stokol; Priscila B S Serpa; Marjory B Brooks; Thomas Divers; Sally Ness
Journal:  Front Vet Sci       Date:  2018-05-28

7.  Effect of valacyclovir on EHV-5 viral kinetics in horses with equine multinodular pulmonary fibrosis.

Authors:  Charlotte A Easton-Jones; John E Madigan; Samantha Barnum; Lara K Maxwell; Sandra D Taylor; Terry Arnesen; Nicola Pusterla
Journal:  J Vet Intern Med       Date:  2018-09-17       Impact factor: 3.333

8.  Investigation of an EHV-1 Outbreak in the United States Caused by a New H752 Genotype.

Authors:  Nicola Pusterla; Samantha Barnum; Julia Miller; Sarah Varnell; Barbara Dallap-Schaer; Helen Aceto; Aliza Simeone
Journal:  Pathogens       Date:  2021-06-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.